Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma

Nat Clin Pract Oncol. 2008 Jan;5(1):2-3. doi: 10.1038/ncponc1004. Epub 2007 Nov 13.
No abstract available

MeSH terms

  • Chemotherapy, Adjuvant* / economics
  • Chemotherapy, Adjuvant* / statistics & numerical data
  • Controlled Clinical Trials as Topic / statistics & numerical data
  • Cost-Benefit Analysis
  • Disease-Free Survival
  • Follow-Up Studies
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / economics
  • Immunologic Factors / therapeutic use*
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / economics
  • Interferon-alpha / therapeutic use*
  • Lymphatic Metastasis
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / pathology
  • Melanoma / secondary
  • Meta-Analysis as Topic
  • Multicenter Studies as Topic / statistics & numerical data
  • Neoplasm Staging
  • Recombinant Proteins
  • Risk
  • Survival Analysis
  • Treatment Outcome

Substances

  • Immunologic Factors
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins